{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T16:39:58Z","timestamp":1782837598815,"version":"3.54.5"},"reference-count":185,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Disease Clinics of North America"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.idc.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T02:02:03Z","timestamp":1589940123000},"page":"359-388","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["JC Polyomavirus Infection Potentiated by Biologics"],"prefix":"10.1016","volume":"34","author":[{"given":"Ashrit","family":"Multani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dora Y.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7712","key":"10.1016\/j.idc.2020.02.007_bib1","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1016\/S0140-6736(71)91777-6","article-title":"Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy","volume":"1","author":"Padgett","year":"1971","journal-title":"Lancet"},{"issue":"1\u20132","key":"10.1016\/j.idc.2020.02.007_bib2","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jneuroim.2011.07.003","article-title":"Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy","volume":"238","author":"Harrison","year":"2011","journal-title":"J\u00a0Neuroimmunol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib3","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1212\/01.WNL.0000081306.86961.33","article-title":"Productive infection of cerebellar granule cell neurons by JC virus in an HIV+ individual","volume":"61","author":"Du Pasquier","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib4","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ana.20431","article-title":"JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy","volume":"57","author":"Koralnik","year":"2005","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/NEN.0b013e3181912570","article-title":"Frequent infection of cerebellar granule cell neurons by polyomavirus JC in progressive multifocal leukoencephalopathy","volume":"68","author":"W\u00fcthrich","year":"2009","journal-title":"J\u00a0Neuropathol Exp Neurol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib6","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/ana.21619","article-title":"Fulminant JC virus encephalopathy with productive infection of cortical pyramidal neurons","volume":"65","author":"W\u00fcthrich","year":"2009","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.24192","article-title":"A\u00a0fatal case of JC virus meningitis presenting with hydrocephalus in a human immunodeficiency virus-seronegative patient","volume":"76","author":"Agnihotri","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.idc.2020.02.007_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.med.080708.082655","article-title":"Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies","volume":"61","author":"Major","year":"2010","journal-title":"Annu Rev Med"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib9","first-page":"475","article-title":"Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature","volume":"62","author":"Levy","year":"1985","journal-title":"J\u00a0Neurosurg"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-107-1-78","article-title":"Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases","volume":"107","author":"Berger","year":"1987","journal-title":"Ann Intern Med"},{"issue":"15","key":"10.1016\/j.idc.2020.02.007_bib11","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.idc.2020.02.007_bib12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.12659\/AJCR.911521","article-title":"Progressive multifocal leukoencephalopathy in the absence of typical radiological changes: can we make a diagnosis?","volume":"20","author":"AlTahan","year":"2019","journal-title":"Am J Case Rep"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2020.02.007_bib13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1080\/13550280390195298","article-title":"The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology","volume":"9","author":"Cinque","year":"2003","journal-title":"J\u00a0Neurovirol"},{"issue":"10","key":"10.1016\/j.idc.2020.02.007_bib14","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/jnnp-2013-304897","article-title":"Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients","volume":"84","author":"Dahlhaus","year":"2013","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1086\/595299","article-title":"Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study","volume":"199","author":"Engsig","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2020.02.007_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/0-387-32957-9_2","article-title":"Discovery and epidemiology of the human polyomaviruses BK virus (BKV) and JC virus (JCV)","volume":"577","author":"Knowles","year":"2006","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib17","doi-asserted-by":"crossref","first-page":"e1000363","DOI":"10.1371\/journal.ppat.1000363","article-title":"Seroepidemiology of human polyomaviruses","volume":"5","author":"Kean","year":"2009","journal-title":"PLoS Pathog"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib18","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/597126","article-title":"Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors","volume":"199","author":"Egli","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.idc.2020.02.007_bib19","series-title":"Polyomaviruses and human diseases","author":"Ahsan","year":"2006"},{"issue":"Suppl 1","key":"10.1016\/j.idc.2020.02.007_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13550280390195397","article-title":"Low prevalence of progressive multifocal leukoencephalopathy in India and Africa: is there a biological explanation?","volume":"9","author":"Shankar","year":"2003","journal-title":"J\u00a0Neurovirol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jcp.20266","article-title":"The agnoprotein of polyomaviruses: a multifunctional auxiliary protein","volume":"204","author":"Khalili","year":"2005","journal-title":"J\u00a0Cell Physiol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib22","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1128\/JVI.75.3.1476-1486.2001","article-title":"Interaction of JC virus agno protein with T antigen modulates transcription and replication of the viral genome in glial cells","volume":"75","author":"Safak","year":"2001","journal-title":"J\u00a0Virol"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.virol.2010.01.011","article-title":"The polyomavirus BK agnoprotein co-localizes with lipid droplets","volume":"399","author":"Unterstab","year":"2010","journal-title":"Virology"},{"issue":"5700","key":"10.1016\/j.idc.2020.02.007_bib24","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1103492","article-title":"The human polyomavirus, JCV, uses serotonin receptors to infect cells","volume":"306","author":"Elphick","year":"2004","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.chom.2010.09.004","article-title":"Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif","volume":"8","author":"Neu","year":"2010","journal-title":"Cell Host Microbe"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.virol.2008.12.021","article-title":"The Polyomaviridae: contributions of virus structure to our understanding of virus receptors and infectious entry","volume":"384","author":"Neu","year":"2009","journal-title":"Virology"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s40588-017-0069-3","article-title":"JC polyomavirus attachment and entry: potential sites for PML therapeutics","volume":"4","author":"Mayberry","year":"2017","journal-title":"Curr Clin Microbiol Rep"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib28","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1128\/JCM.02472-08","article-title":"Polyomavirus shedding in the stool of healthy adults","volume":"47","author":"Vanchiere","year":"2009","journal-title":"J\u00a0Clin Microbiol"},{"issue":"21","key":"10.1016\/j.idc.2020.02.007_bib29","doi-asserted-by":"crossref","first-page":"10290","DOI":"10.1128\/JVI.75.21.10290-10299.2001","article-title":"Potential transmission of human polyomaviruses through the gastrointestinal tract after exposure to virions or viral DNA","volume":"75","author":"Bofill-Mas","year":"2001","journal-title":"J\u00a0Virol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib30","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1128\/AEM.66.1.238-245.2000","article-title":"Documenting the epidemiologic patterns of polyomaviruses in human populations by studying their presence in urban sewage","volume":"66","author":"Bofill-Mas","year":"2000","journal-title":"Appl Environ Microbiol"},{"issue":"12","key":"10.1016\/j.idc.2020.02.007_bib31","doi-asserted-by":"crossref","first-page":"9918","DOI":"10.1128\/JVI.72.12.9918-9923.1998","article-title":"Detection of JC virus DNA in human tonsil tissue: evidence for site of initial viral infection","volume":"72","author":"Monaco","year":"1998","journal-title":"J\u00a0Virol"},{"issue":"10","key":"10.1016\/j.idc.2020.02.007_bib32","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1128\/jcm.32.10.2359-2363.1994","article-title":"Transmission of the human polyomavirus JC virus occurs both within the family and outside the family","volume":"32","author":"Kitamura","year":"1994","journal-title":"J\u00a0Clin Microbiol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib33","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1128\/jcm.33.6.1448-1451.1995","article-title":"Parent-to-child transmission is relatively common in the spread of the human polyomavirus JC virus","volume":"33","author":"Kunitake","year":"1995","journal-title":"J\u00a0Clin Microbiol"},{"issue":"Pt 5","key":"10.1016\/j.idc.2020.02.007_bib34","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1099\/vir.0.028571-0","article-title":"Serological evidence of vertical transmission of JC and BK polyomaviruses in humans","volume":"92","author":"Boldorini","year":"2011","journal-title":"J\u00a0Gen Virol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/infdis\/147.4.676","article-title":"Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues","volume":"147","author":"Chesters","year":"1983","journal-title":"J\u00a0Infect Dis"},{"issue":"7","key":"10.1016\/j.idc.2020.02.007_bib36","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/j.1469-0691.2004.00882.x","article-title":"Prevalence and patterns of polyomavirus urinary excretion in immunocompetent adults and children","volume":"10","author":"Polo","year":"2004","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib37","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/infdis\/167.1.13","article-title":"Incidence of BK virus and JC virus viruria in human immunodeficiency virus-infected and -uninfected subjects","volume":"167","author":"Markowitz","year":"1993","journal-title":"J\u00a0Infect Dis"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib38","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1128\/jvi.65.8.4515-4519.1991","article-title":"BK virus and JC virus shed during pregnancy have predominantly archetypal regulatory regions","volume":"65","author":"Markowitz","year":"1991","journal-title":"J\u00a0Virol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1128\/jcm.35.5.1255-1257.1997","article-title":"Persistent JC virus (JCV) infection is demonstrated by continuous shedding of the same JCV strains","volume":"35","author":"Kitamura","year":"1997","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.idc.2020.02.007_bib40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/0-387-32957-9_8","article-title":"Human polyomavirus JC and BK persistent infection","volume":"577","author":"Doerries","year":"2006","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/13550289909021994","article-title":"Detection and typing of JC virus in autopsy brains and extraneural organs of AIDS patients and non-immunocompromised individuals","volume":"5","author":"Caldarelli-Stefano","year":"1999","journal-title":"J\u00a0Neurovirol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib42","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1086\/597117","article-title":"Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation","volume":"199","author":"Tan","year":"2009","journal-title":"J\u00a0Infect Dis"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib43","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/13550280802356837","article-title":"Rearrangement of the JC virus regulatory region sequence in the bone marrow of a patient with rheumatoid arthritis and progressive multifocal leukoencephalopathy","volume":"14","author":"Marzocchetti","year":"2008","journal-title":"J\u00a0Neurovirol"},{"issue":"18","key":"10.1016\/j.idc.2020.02.007_bib44","doi-asserted-by":"crossref","first-page":"9200","DOI":"10.1128\/JVI.00609-10","article-title":"JC virus latency in the brain and extraneural organs of patients with and without progressive multifocal leukoencephalopathy","volume":"84","author":"Tan","year":"2010","journal-title":"J\u00a0Virol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib45","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s13365-014-0294-y","article-title":"Immunology of progressive multifocal leukoencephalopathy","volume":"21","author":"Jelcic","year":"2015","journal-title":"J\u00a0Neurovirol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib46","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3109\/13550289909029484","article-title":"Detection of JC virus DNA in peripheral blood cell subpopulations of HIV-1-infected individuals","volume":"5","author":"Koralnik","year":"1999","journal-title":"J\u00a0Neurovirol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib47","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ana.410310426","article-title":"Detection of JC virus DNA in peripheral lymphocytes from patients with and without progressive multifocal leukoencephalopathy","volume":"31","author":"Tornatore","year":"1992","journal-title":"Ann Neurol"},{"key":"10.1016\/j.idc.2020.02.007_bib48","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fimmu.2015.00241","article-title":"B\u00a0cells and progressive multifocal leukoencephalopathy: search for the missing link","volume":"6","author":"Durali","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.idc.2020.02.007_bib49","doi-asserted-by":"crossref","first-page":"839719","DOI":"10.1155\/2013\/839719","article-title":"New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy","volume":"2013","author":"Bellizzi","year":"2013","journal-title":"Clin Dev Immunol"},{"issue":"Pt 12","key":"10.1016\/j.idc.2020.02.007_bib50","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1099\/vir.0.023184-0","article-title":"Transcription factor Spi-B binds unique sequences present in the tandem repeat promoter\/enhancer of JC virus and supports viral activity","volume":"91","author":"Marshall","year":"2010","journal-title":"J\u00a0Gen Virol"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib51","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1086\/653823","article-title":"Human polyomavirus JC (JCV) infection of human B lymphocytes: a possible mechanism for JCV transmigration across the blood-brain barrier","volume":"202","author":"Chapagain","year":"2010","journal-title":"J\u00a0Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib52","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jamaneurol.2013.4668","article-title":"JC polyomavirus granule cell neuronopathy in a patient treated with rituximab","volume":"71","author":"Dang","year":"2014","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib53","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s13365-014-0303-1","article-title":"A\u00a0risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy","volume":"21","author":"Chahin","year":"2015","journal-title":"J\u00a0Neurovirol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib54","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","article-title":"Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps","volume":"3","author":"Zaheer","year":"2012","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrrheum.2014.167","article-title":"Sorting out the risks in progressive multifocal leukoencephalopathy","volume":"11","author":"Calabrese","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib56","first-page":"57","article-title":"A\u00a0review of neurologic complications of biologic therapy in plaque psoriasis","volume":"101","author":"Lin","year":"2018","journal-title":"Cutis"},{"key":"10.1016\/j.idc.2020.02.007_bib57","first-page":"643216","article-title":"JC virus PCR detection is not infallible: a fulminant case of progressive multifocal leukoencephalopathy with false-negative cerebrospinal fluid studies despite progressive clinical course and radiological findings","volume":"2015","author":"Babi","year":"2015","journal-title":"Case Rep Neurol Med"},{"issue":"7","key":"10.1016\/j.idc.2020.02.007_bib58","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1136\/annrheumdis-2013-204978","article-title":"A\u00a0case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab","volume":"73","author":"Ray","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib59","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/art.27687","article-title":"A\u00a0case of progressive multifocal leukoencephalopathy in a patient treated with infliximab","volume":"62","author":"Kumar","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib60","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/NRL.0b013e318247b868","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with etanercept","volume":"18","author":"Graff-Radford","year":"2012","journal-title":"Neurologist"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4997\/jrcpe.2016.305","article-title":"Progressive multifocal leukoencephalopathy associated with infliximab","volume":"46","author":"Sammut","year":"2016","journal-title":"J\u00a0R Coll Physicians Edinb"},{"issue":"5 Suppl 35","key":"10.1016\/j.idc.2020.02.007_bib62","first-page":"S134","article-title":"Demyelination and inhibition of tumor necrosis factor (TNF)","volume":"22","author":"Magnano","year":"2004","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib63","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jmv.23525","article-title":"Latent viral infections in young patients with inflammatory diseases treated with biological agents: prevalence of JC virus genotype 2","volume":"85","author":"Comar","year":"2013","journal-title":"J\u00a0Med Virol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s13365-011-0036-3","article-title":"Polyomavirus JC reactivation and noncoding control region sequence analysis in pediatric Crohn\u2019s disease patients treated with infliximab","volume":"17","author":"Bellizzi","year":"2011","journal-title":"J\u00a0Neurovirol"},{"issue":"12","key":"10.1016\/j.idc.2020.02.007_bib65","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/jcp.24089","article-title":"Reactivation of human polyomavirus JC in patients affected by psoriasis vulgaris and psoriatic arthritis and treated with biological drugs: preliminary results","volume":"227","author":"Nardis","year":"2012","journal-title":"J\u00a0Cell Physiol"},{"key":"10.1016\/j.idc.2020.02.007_bib66","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1743-422X-10-298","article-title":"Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study","volume":"10","author":"Bellizzi","year":"2013","journal-title":"Virol J"},{"issue":"16","key":"10.1016\/j.idc.2020.02.007_bib67","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1002\/cncr.28712","article-title":"Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project","volume":"120","author":"Carson","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib68","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","article-title":"Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project","volume":"10","author":"Carson","year":"2009","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.idc.2020.02.007_bib69","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib70","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J\u00a0Neurovirol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.007_bib71","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.idc.2020.02.007_bib72","first-page":"892047","article-title":"Late occurrence of PML in a patient treated for lymphoma with immunomodulatory chemotherapies, bendamustine, rituximab, and ibritumomab tiuxetan","volume":"2015","author":"Lane","year":"2015","journal-title":"Case Rep Neurol Med"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib73","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1017\/S0317167100012105","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"38","author":"Keene","year":"2011","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib74","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3324\/haematol.2014.118158","article-title":"Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia","volume":"100","author":"Moreno","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib75","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1016\/S2352-3026(17)30019-4","article-title":"Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial","volume":"4","author":"Jones","year":"2017","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib76","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s00277-018-3552-x","article-title":"Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia","volume":"98","author":"Pejsa","year":"2019","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib77","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","article-title":"Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system","volume":"15","author":"Raisch","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib78","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1136\/jim-2016-000339","article-title":"Update on disease-modifying therapies for multiple sclerosis","volume":"65","author":"Vargas","year":"2017","journal-title":"J\u00a0Investig Med"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib79","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11910-017-0800-8","article-title":"Infections in patients receiving multiple sclerosis disease-modifying therapies","volume":"17","author":"Grebenciucova","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib80","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40263-018-0488-6","article-title":"Efficacy and safety of the newer multiple sclerosis drugs approved since 2010","volume":"32","author":"Faissner","year":"2018","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.idc.2020.02.007_bib81","first-page":"2342","article-title":"Anti-JC virus antibody index changes in rituximab-treated multiple sclerosis patients","volume":"265","author":"Baber","year":"2018","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib82","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.idc.2020.02.007_bib83","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2217\/fon-2016-0084","article-title":"Obinutuzumab for the treatment of indolent lymphoma","volume":"12","author":"Edelmann","year":"2016","journal-title":"Future Oncol"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib84","doi-asserted-by":"crossref","first-page":"ofy174","DOI":"10.1093\/ofid\/ofy174","article-title":"Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management","volume":"5","author":"Epstein","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.idc.2020.02.007_bib85","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.msard.2017.01.006","article-title":"Classifying PML risk with disease modifying therapies","volume":"12","author":"Berger","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/17474086.2013.814434","article-title":"Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma","volume":"6","author":"Lai","year":"2013","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib87","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.3109\/10428194.2012.676170","article-title":"Progressive multifocal leukoencephalopathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin","volume":"53","author":"Wagner-Johnston","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"10.1016\/j.idc.2020.02.007_bib88","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1212\/WNL.0b013e3182749f17","article-title":"PML-IRIS in a patient treated with brentuximab","volume":"79","author":"von Geldern","year":"2012","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.idc.2020.02.007_bib89","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.clineuro.2012.03.019","article-title":"Brentuximab associated progressive multifocal leukoencephalopathy","volume":"114","author":"Jalan","year":"2012","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib90","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/phar.1170","article-title":"Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate","volume":"33","author":"Newland","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.007_bib91","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/j.cmi.2018.03.022","volume":"24","author":"Drgona","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"10.1016\/j.idc.2020.02.007_bib92","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1177\/0961203314524292","article-title":"A\u00a0case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab","volume":"23","author":"Fredericks","year":"2014","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib93","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3899\/jrheum.140577","article-title":"Progressive multifocal leukoencephalopathy associated with belimumab in a patient with systemic lupus erythematosus","volume":"42","author":"Leblanc-Trudeau","year":"2015","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.idc.2020.02.007_bib94","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1111\/j.1469-0691.2011.03653.x","article-title":"Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies","volume":"17","author":"Tavazzi","year":"2011","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib95","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.autrev.2008.07.006","article-title":"Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?","volume":"8","author":"Molloy","year":"2008","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib96","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000444874","article-title":"Progressive multifocal leukoencephalopathy and systemic lupus erythematosus: focus on etiology","volume":"8","author":"Berntsson","year":"2016","journal-title":"Case Rep Neurol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib97","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/s12016-012-8327-x","article-title":"Systemic lupus erythematosus, progressive multifocal leukoencephalopathy, and T-CD4+ lymphopenia","volume":"43","author":"Brand\u00e3o","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"issue":"12","key":"10.1016\/j.idc.2020.02.007_bib98","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/TP.0b013e3182007b95","article-title":"An integrated safety profile analysis of belatacept in kidney transplant recipients","volume":"90","author":"Griny\u00f3","year":"2010","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib99","doi-asserted-by":"crossref","first-page":"ofx100","DOI":"10.1093\/ofid\/ofx100","article-title":"Refractory T-cell anergy and rapidly fatal progressive multifocal leukoencephalopathy after prolonged CTLA4 therapy","volume":"4","author":"Dekeyser","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib100","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1517\/14740338.2015.986455","article-title":"Safety of off-label biologicals in systemic lupus erythematosus","volume":"14","author":"Aringer","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.007_bib101","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.007_bib102","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib103","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1056\/NEJMoa051847","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with natalizumab","volume":"353","author":"Langer-Gould","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib104","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1056\/NEJMoa051586","article-title":"Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn\u2019s disease","volume":"353","author":"Van Assche","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJMoa051782","article-title":"Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis","volume":"353","author":"Kleinschmidt-DeMasters","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib106","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMoa0810257","article-title":"Treatment of progressive multifocal leukoencephalopathy associated with natalizumab","volume":"361","author":"Wenning","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib107","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa0810316","article-title":"Progressive multifocal leukoencephalopathy after natalizumab monotherapy","volume":"361","author":"Lind\u00e5","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.idc.2020.02.007_bib108","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.idc.2020.02.007_bib109","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1097\/MIB.0000000000000373","article-title":"Efficacy and safety of natalizumab and vedolizumab for the management of Crohn\u2019s disease: a systematic review and meta-analysis","volume":"21","author":"Chandar","year":"2015","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib110","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.idc.2020.02.007_bib111","doi-asserted-by":"crossref","DOI":"10.1007\/s10072-019-03959-4","article-title":"Four cases of natalizumab-related PML: a less severe course in extended interval dosing?","author":"Scarpazza","year":"2019","journal-title":"Neurol Sci"},{"issue":"12","key":"10.1016\/j.idc.2020.02.007_bib112","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0000000000003739","article-title":"Natalizumab-associated PML: challenges with incidence, resulting risk, and risk stratification","volume":"88","author":"Schwab","year":"2017","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib113","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib114","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A\u00a0second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J\u00a0Clin Virol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib115","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1212\/CPJ.0000000000000457","article-title":"Progressive multifocal leukoencephalopathy with extended natalizumab dosing","volume":"8","author":"Baldassari","year":"2018","journal-title":"Neurol Clin Pract"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib116","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib117","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib118","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.14075","article-title":"Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease","volume":"46","author":"Bye","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib119","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ibd\/izx097","article-title":"What is the risk of progressive multifocal leukoencephalopathy in patients with ulcerative colitis or Crohn\u2019s disease treated with vedolizumab?","volume":"24","author":"Card","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib120","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1093\/ibd\/izy153","article-title":"Low frequency of opportunistic infections in patients receiving vedolizumab in clinical trials and post-marketing setting","volume":"24","author":"Ng","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib121","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40264-018-00783-1","article-title":"Benefit-risk assessment of vedolizumab in the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"42","author":"Battat","year":"2019","journal-title":"Drug Saf"},{"issue":"13","key":"10.1016\/j.idc.2020.02.007_bib122","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib123","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40264-018-0669-8","article-title":"A\u00a0programme for risk assessment and minimisation of progressive multifocal leukoencephalopathy developed for vedolizumab clinical trials","volume":"41","author":"Parikh","year":"2018","journal-title":"Drug Saf"},{"issue":"1\u20132","key":"10.1016\/j.idc.2020.02.007_bib124","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000449077","article-title":"Leukocyte anti-trafficking strategies: current status and future directions","volume":"35","author":"Sands","year":"2017","journal-title":"Dig Dis"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib125","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/11537510-000000000-00000","article-title":"Progressive multifocal leukoencephalopathy and newer biological agents","volume":"33","author":"Berger","year":"2010","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib126","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/14740338.2011.524925","article-title":"Efalizumab","volume":"10","author":"Talamonti","year":"2011","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib127","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/pds.3320","article-title":"Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)","volume":"21","author":"Schmedt","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib128","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archdermatol.2009.175","article-title":"Progressive multifocal leukoencephalopathy, efalizumab, and immunosuppression: a cautionary tale for dermatologists","volume":"145","author":"Korman","year":"2009","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib129","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1365-4632.2010.04475.x","article-title":"Progressive multifocal leukoencephalopathy and antipsoriatic drugs: assessing the risk of immunosuppressive treatments","volume":"49","author":"Di Lernia","year":"2010","journal-title":"Int J Dermatol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib130","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4161\/mabs.1.6.9884","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"1","author":"Berger","year":"2009","journal-title":"MAbs"},{"issue":"7","key":"10.1016\/j.idc.2020.02.007_bib131","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1212\/WNL.0b013e3182478d4b","article-title":"Fatal PML associated with efalizumab therapy: insights into integrin \u03b1L\u03b22 in JC virus control","volume":"78","author":"Schwab","year":"2012","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib132","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s00277-001-0394-7","article-title":"Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin\u2019s lymphomas: a multicenter phase I\/II study","volume":"81","author":"Uppenkamp","year":"2002","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib133","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/504811","article-title":"Infectious complications associated with alemtuzumab use for lymphoproliferative disorders","volume":"43","author":"Martin","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib134","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.healun.2008.12.010","article-title":"Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant","volume":"28","author":"Waggoner","year":"2009","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1016\/j.idc.2020.02.007_bib135","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-201781","article-title":"Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab","volume":"2014","author":"Isidoro","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib136","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/ajh.24265","article-title":"A\u00a0phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908)","volume":"91","author":"Zent","year":"2016","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib137","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1517\/14740338.2015.1093620","article-title":"Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"14","author":"Faulkner","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib138","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/practneurol-2015-001355","article-title":"Switching patients at high risk of PML from natalizumab to another disease-modifying therapy","volume":"16","author":"Giovannoni","year":"2016","journal-title":"Pract Neurol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib139","first-page":"165","article-title":"Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation","volume":"266","author":"Pfeuffer","year":"2019","journal-title":"J\u00a0Neurol"},{"issue":"3","key":"10.1016\/j.idc.2020.02.007_bib140","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.autrev.2018.09.012","article-title":"A\u00a0review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis","volume":"18","author":"Sellner","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib141","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1177\/1352458519832259","article-title":"Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy","volume":"25","author":"Gerevini","year":"2019","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.idc.2020.02.007_bib142","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-015-0286-3","article-title":"Drug-induced progressive multifocal leukoencephalopathy: a comprehensive analysis of the WHO adverse drug reaction database","volume":"29","author":"Melis","year":"2015","journal-title":"CNS Drugs"},{"issue":"17","key":"10.1016\/j.idc.2020.02.007_bib143","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa1815039","article-title":"Pembrolizumab treatment for progressive multifocal leukoencephalopathy","volume":"380","author":"Cortese","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"17","key":"10.1016\/j.idc.2020.02.007_bib144","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJMc1817193","article-title":"Treatment of progressive multifocal leukoencephalopathy with pembrolizumab","volume":"380","author":"Rauer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib145","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s13365-019-00738-x","article-title":"Progressive multifocal leukoencephalopathy treated with nivolumab","volume":"25","author":"Hoang","year":"2019","journal-title":"J\u00a0Neurovirol"},{"issue":"17","key":"10.1016\/j.idc.2020.02.007_bib146","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1056\/NEJMc1816198","article-title":"Treatment of progressive multifocal leukoencephalopathy with nivolumab","volume":"380","author":"Walter","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.idc.2020.02.007_bib147","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3201\/eid2408.180460","article-title":"Progressive multifocal leukoencephalopathy after treatment with nivolumab","volume":"24","author":"Martinot","year":"2018","journal-title":"Emerg Infect Dis"},{"issue":"17","key":"10.1016\/j.idc.2020.02.007_bib148","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMe1904140","article-title":"Can immune checkpoint inhibitors keep JC virus in check?","volume":"380","author":"Koralnik","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.007_bib149","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.cmi.2018.02.009","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (intracellular signaling pathways: tyrosine kinase and mTOR inhibitors)","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib150","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/bjh.14322","article-title":"Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia","volume":"180","author":"Bennett","year":"2018","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib151","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1159\/000490617","article-title":"Ibrutinib use complicated by progressive multifocal leukoencephalopathy","volume":"95","author":"Hsiehchen","year":"2018","journal-title":"Oncology"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib152","doi-asserted-by":"crossref","first-page":"548","DOI":"10.4143\/crt.2016.110","article-title":"Progressive multifocal leukoencephalopathy after ibrutinib therapy for chronic lymphocytic leukemia","volume":"49","author":"Lutz","year":"2017","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.idc.2020.02.007_bib153","series-title":"Calquence (acalabrutinib) [package insert]","year":"2017"},{"key":"10.1016\/j.idc.2020.02.007_bib154","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.cmi.2017.12.027","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (cell surface receptors and associated signaling pathways)","volume":"24","author":"Aguilar-Company","year":"2018","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib156","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s13365-017-0558-4","article-title":"Fatal ruxolitinib-related JC virus meningitis","volume":"23","author":"Ballesta","year":"2017","journal-title":"J\u00a0Neurovirol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib157","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1212\/WNL.0000000000002312","article-title":"Eculizumab-related progressive multifocal leukoencephalopathy","volume":"86","author":"G\u00f3mez-Cibeira","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib158","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.3747\/co.25.3674","article-title":"Progressive multifocal leukoencephalopathy during ixazomib-based chemotherapy","volume":"25","author":"Sawicki","year":"2018","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib159","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1474-4422(10)70040-5","article-title":"Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis","volume":"9","author":"Tan","year":"2010","journal-title":"Lancet Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.idc.2020.02.007_bib160","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.3949\/ccjm.78.s2.09","article-title":"A\u00a0rational approach to PML for the clinician","volume":"78","author":"Calabrese","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.idc.2020.02.007_bib161","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.msard.2019.02.019","article-title":"The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings","volume":"30","author":"Kolcava","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.idc.2020.02.007_bib162","doi-asserted-by":"crossref","first-page":"e01332","DOI":"10.1002\/brb3.1332","article-title":"Conversion and reversion of anti-John Cunningham virus antibody serostatus: a prospective study","volume":"9","author":"Auer","year":"2019","journal-title":"Brain Behav"},{"key":"10.1016\/j.idc.2020.02.007_bib163","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jocn.2018.10.128","article-title":"Seroconversion of JCV antibodies is strongly associated to natalizumab therapy","volume":"61","author":"Fragoso","year":"2019","journal-title":"J\u00a0Clin Neurosci"},{"issue":"12","key":"10.1016\/j.idc.2020.02.007_bib164","first-page":"2409","article-title":"Natalizumab therapy is associated with changes in serum JC virus antibody indices over time","volume":"264","author":"Peters","year":"2017","journal-title":"J\u00a0Neurol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib165","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.idc.2020.02.007_bib166","article-title":"Should frequent MRI monitoring be performed in natalizumab-treated MS patients? A contribution to a recent debate","author":"Scarpazza","year":"2019","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib167","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/ana.25523","article-title":"Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy","volume":"86","author":"Loonstra","year":"2019","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib168","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ana.25437","article-title":"Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients","volume":"85","author":"Dalla Costa","year":"2019","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib169","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41598-018-36535-5","article-title":"Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients","volume":"9","author":"Iannetta","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.rdc.2016.09.009","article-title":"The risk of progressive multifocal leukoencephalopathy in the biologic era: prevention and management","volume":"43","author":"Molloy","year":"2017","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl 201","key":"10.1016\/j.idc.2020.02.007_bib171","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ane.12840","article-title":"The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy","volume":"136","author":"Reuwer","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"11","key":"10.1016\/j.idc.2020.02.007_bib172","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.cgh.2015.05.022","article-title":"Prevalence of antibodies against JC virus in patients with refractory crohn\u2019s disease and effects of natalizumab therapy","volume":"13","author":"Bellaguarda","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib173","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.semarthrit.2015.06.003","article-title":"Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis","volume":"45","author":"Borie","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.idc.2020.02.007_bib174","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/jmv.23339","article-title":"Investigation of polyomaviruses replication in pediatric patients with nephropathy receiving rituximab","volume":"84","author":"Delbue","year":"2012","journal-title":"J\u00a0Med Virol"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib175","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3109\/03009742.2015.1135980","article-title":"JC virus reactivation in patients with autoimmune rheumatic diseases treated with rituximab","volume":"45","author":"Dom\u00ednguez-Mozo","year":"2016","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib176","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00430-015-0390-5","article-title":"Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics","volume":"204","author":"Verheyen","year":"2015","journal-title":"Med Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.idc.2020.02.007_bib177","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ana.23893","article-title":"JC virus antibody status underestimates infection rates","volume":"74","author":"Berger","year":"2013","journal-title":"Ann Neurol"},{"issue":"5","key":"10.1016\/j.idc.2020.02.007_bib178","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1128\/AAC.01614-08","article-title":"Identification and characterization of mefloquine efficacy against JC virus in\u00a0vitro","volume":"53","author":"Brickelmaier","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib179","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1212\/NXI.0000000000000323","article-title":"Severe early natalizumab-associated PML in MS: effective control of PML-IRIS with maraviroc","volume":"4","author":"Bsteh","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib180","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/archneurol.2008.557","article-title":"Mirtazapine use in human immunodeficiency virus-infected patients with progressive multifocal leukoencephalopathy","volume":"66","author":"Cettomai","year":"2009","journal-title":"Arch Neurol"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib181","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1212\/NXI.0000000000000325","article-title":"Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS","volume":"4","author":"Hodecker","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.idc.2020.02.007_bib182","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14787210.2016.1132162","article-title":"Treatment options for progressive multifocal leukoencephalopathy in HIV-infected persons: current status and future directions","volume":"14","author":"Loignon","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"6","key":"10.1016\/j.idc.2020.02.007_bib183","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"issue":"4","key":"10.1016\/j.idc.2020.02.007_bib184","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s12185-008-0168-2","article-title":"Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature","volume":"88","author":"Yokoyama","year":"2008","journal-title":"Int J Hematol"},{"issue":"15","key":"10.1016\/j.idc.2020.02.007_bib185","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMoa1801540","article-title":"Allogeneic BK virus\u2013specific T\u00a0cells for progressive multifocal leukoencephalopathy","volume":"379","author":"Muftuoglu","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Infectious Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089155202030009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089155202030009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:18:32Z","timestamp":1760195912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089155202030009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":185,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S089155202030009X"],"URL":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.007","relation":{},"ISSN":["0891-5520"],"issn-type":[{"value":"0891-5520","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"JC Polyomavirus Infection Potentiated by Biologics","name":"articletitle","label":"Article Title"},{"value":"Infectious Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idc.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}